CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy induces a high rate of complete remission (CR) in children with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL) [1, 2]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.